UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

Translating cancer research into targeted therapeutics

Nature (London), 2010-09, Vol.467 (7315), p.543-549

2010

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Gene therapy, 2008-06, Vol.15 (12), p.911-920

2008

Link zum Volltext

Verfügbarkeit prüfen

Analysis of DNA methylation in single circulating tumor cells

Oncogene, 2017-06, Vol.36 (23), p.3223-3231

2017

Link zum Volltext

Verfügbarkeit prüfen

A decade of clinical development of PARP inhibitors in perspective

Annals of oncology, 2019-09, Vol.30 (9), p.1437-1447

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

British journal of cancer, 2004-07, Vol.91 (1), p.50-55

2004

Link zum Volltext

Verfügbarkeit prüfen

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

British journal of cancer, 2014-08, Vol.111 (5), p.828-836

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

British journal of cancer, 2010-06, Vol.103 (1), p.12-17

2010

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.1039-1046

2014

Link zum Volltext

Verfügbarkeit prüfen

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

British journal of cancer, 2010-07, Vol.103 (3), p.332-339

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Annals of oncology, 2004-12, Vol.15 (12), p.1825-1833

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

British journal of cancer, 2008-06, Vol.98 (12), p.1951-1958

2008

Link zum Volltext

Verfügbarkeit prüfen

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Oncology, 2012-08, Vol.83 (4), p.177-182

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

British journal of cancer, 2007-11, Vol.97 (10), p.1338-1343

2007

Link zum Volltext

Verfügbarkeit prüfen

The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

British journal of cancer, 2015-03, Vol.112 (7), p.1157-1165

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

British journal of cancer, 2008-03, Vol.98 (5), p.894-899

2008

Link zum Volltext

Verfügbarkeit prüfen

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1918-1925

2018

Link zum Volltext

Verfügbarkeit prüfen

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

British journal of cancer, 2012-04, Vol.106 (8), p.1379-1385

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

British journal of cancer, 2002-03, Vol.86 (5), p.680-685

2002

Link zum Volltext

Verfügbarkeit prüfen

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

British journal of cancer, 2015-12, Vol.113 (11), p.1541-1547

2015

Link zum Volltext

Verfügbarkeit prüfen

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

British journal of cancer, 2010-08, Vol.103 (5), p.607-612

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial outcomes in older patients with advanced solid tumours

British journal of cancer, 2016-02, Vol.114 (3), p.262-268

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Annals of oncology, 2006-08, Vol.17 (8), p.1313-1319

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of ONO-4007, a Synthetic Analogue of the Lipid A Moiety of Bacterial Lipopolysaccharide

Clinical cancer research, 2000-02, Vol.6 (2), p.397-405

2000

Link zum Volltext

Verfügbarkeit prüfen

Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages

Experimental hematology, 1999-12, Vol.27 (12), p.1735-1745

1999

Link zum Volltext

Verfügbarkeit prüfen

The ErbB receptor family: a therapeutic target for cancer

Trends in Molecular Medicine, 2002-01, Vol.8 (4), p.S19-S26

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 205

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(188)

Publikationsform

Artikel
(205)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Translating cancer research into targeted therapeutics

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Analysis of DNA methylation in single circulating tumor cells

A decade of clinical development of PARP inhibitors in perspective

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

Phase I trial outcomes in older patients with advanced solid tumours

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Phase I Study of ONO-4007, a Synthetic Analogue of the Lipid A Moiety of Bacterial Lipopolysaccharide

Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages

The ErbB receptor family: a therapeutic target for cancer

Aktive Filter

Suchergebnisse filtern